Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD).

收购扩展了AbbVie的精神病学管线，新增了一种下一代迷幻化合物，该化合物目前正处于治疗重度抑郁症（MDD）的二期临床开发阶段。

NORTH CHICAGO, Ill.

伊利诺伊州北芝加哥市

,

，

Oct. 17, 2025

2025年10月17日

/

/

PRNewswire

美通社

/

/

--

--

AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin.

AbbVie（纽约证券交易所代码：ABBV）今天宣布，已完成对Gilgamesh Pharmaceuticals主要研究候选药物bretisilocin的收购。

Bretisilocin is a novel, short-acting serotonin 5-HT

布雷蒂西洛辛是一种新型、短效的5-HT血清素

2A

2A

receptor agonist and 5-HT releaser currently in Phase 2 clinical development for the treatment of patients with moderate-to-severe major depressive disorder (MDD). This next-generation 5-HT

受体激动剂和5-HT释放剂，目前处于治疗中度至重度重度抑郁症（MDD）患者的2期临床开发阶段。这种下一代5-HT

2A

2A

receptor agonist is designed to help address current development challenges observed with classic psychedelic compounds.

受体激动剂旨在帮助解决目前在经典迷幻化合物开发中遇到的挑战。

'Recent clinical results have demonstrated the potential of bretisilocin to treat patients living with MDD,' said Daniel Mikol, M.D., Ph.D., vice president, neuroscience development, AbbVie. 'With the acquisition now complete, we look forward to accelerating the development of this next-generation compound, reinforcing AbbVie's commitment to delivering innovative, science-driven treatment options for people living with serious mental health conditions.'.

“最近的临床结果已经证明了布雷西里辛治疗MDD患者的潜力，”艾伯维神经科学开发副总裁丹尼尔·米科博士表示。“随着收购的完成，我们期待加速推进这一下一代化合物的开发，进一步巩固艾伯维致力于为患有严重心理健康问题的人群提供创新且科学驱动的治疗选择的承诺。”

For additional background on the acquisition, please read the press release announcing the definitive agreement under which AbbVie will acquire bretisilocin

有关此次收购的更多背景信息，请阅读宣布艾伯维将收购布雷蒂西洛辛的最终协议的新闻稿。

here

这里

.

。

About AbbVie

关于艾伯维

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio.

艾伯维的使命是发现并提供创新的药物和解决方案，以解决当今严重的健康问题，并应对未来的医疗挑战。我们努力在包括免疫学、肿瘤学、神经科学和眼科在内的几个关键治疗领域对人们的生活产生显著影响，并且我们在Allergan Aesthetics产品组合中的产品和服务也发挥着重要作用。

For more information about AbbVie, please visit us at .

欲了解有关艾伯维的更多信息，请访问我们的网站。

www.abbvie.com

www.abbvie.com

. Follow @abbvie on

关注 @abbvie

LinkedIn,

领英，

Facebook

脸书

,

，

Instagram

图享

,

，

X (formerly Twitter)

X（前身为 Twitter）

and

和

YouTube.

YouTube。

Forward-Looking Statements

前瞻性声明

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements.

本新闻稿中的某些声明，或可能被视为《1995年私人证券诉讼改革法案》所指的前瞻性声明。 “相信”、“预期”、“预见”、“预测”等词语及类似表达和未来或条件动词的使用，通常用于识别前瞻性声明。

AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations.

AbbVie提醒，这些前瞻性陈述受到可能导致实际结果与前瞻性陈述中明示或暗示的结果存在重大差异的风险和不确定性的影响。这些风险和不确定性包括但不限于：知识产权方面的挑战、来自其他产品的竞争、研发过程中固有的困难、不利的诉讼或政府行为、适用于我们行业的法律法规的变化、全球宏观经济因素的影响，如经济衰退或不确定性、国际冲突、贸易争端和关税，以及与全球业务运营相关的其他不确定性和风险。

Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, 'Risk Factors,' of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information.

有关可能影响艾伯维运营的经济、竞争、政府、技术及其他因素的更多信息，请参阅艾伯维2024年Form 10-K年度报告的第1A项“风险因素”，该报告已提交给美国证券交易委员会，并通过其后续提交的Form 10-Q季度报告以及其他更新、补充或取代该信息的文件进行更新。

AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law..

AbbVie 不承担任何义务，并明确拒绝因后续事件或发展而公开发布对前瞻性声明的任何修订，除非法律要求。

Media:

媒体：

Liz Tang, Ph.D.

唐丽兹，博士

liz.tang@abbvie.com

丽兹·唐@艾伯维.com

Investors:

投资者：

Liz Shea

莉兹·谢伊

liz.shea@abbvie.com

liz.shea@abbvie.com

SOURCE AbbVie

来源：艾伯维（AbbVie）